Dollars at Work
IMPACT & USE OF FUNDS
Since 2008, The Enbridge® Ride to Conquer Cancer® has raised over $155 million for the Princess Margaret Cancer Centre and currently is Canada’s largest cycling fundraiser.
Funds raised through The Ride support Personalized Cancer Medicine, including research, treatment advances, education and new standards of care at Princess Margaret Cancer Centre.
Princess Margaret Cancer Centre is one of the world’s top 5 cancer centres and is a leader in Personalized Cancer Medicine.
Personalized Cancer Medicine is a multi-faceted, integrated approach to cancer care that focuses on the unique nature of each patient. Because every patient is unique, every patient’s cancer is different. Funds raised through The Ride are enabling the researchers, scientists and doctors at Princess Margaret Cancer Centre to better understand the unique genes of each cancer and each patient, which are leading to more effective, targeted and less toxic treatments for cancer patients in Ontario and around the world.
Funds raised by Riders are put to use immediately at Princess Margaret Cancer Centre and are allocated into four main areas of Personalized Cancer Medicine:
Investing in Progress
We understand how important it is to make smart investments with donor dollars and we strategically invest in projects that have a clear impact on patients. To learn more about how we are investing donor dollars, click here.
Since 2008, The Princess Margaret has also used funds raised through The Ride to support other core cancer areas including:
- Programs - Immune Therapy program led by Dr. Pamela Ohashi and Dr. Tak Mak; Cancer Stem Cell program led by Dr. John Dick and Dr. Ben Neel; and Tumour Hypoxia program led by Dr. Brad Wouters and Dr. Michael Milosevic.
- Research Platforms - Image-Guided Technology and Robotic Surgery; Clinical Trials that support specific cancer types; BioBank initiative.
- People - Over 150 highly-skilled, basic and clinical scientists and over 1,000 people all employed in their research enterprise.